Clinical Trial Update: Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for Allo-QuadCAR01-T, an allogeneic CD19/CD20 CAR-T, in relapsed or refractory B-cell malignancies, currently recruiting in Phase 1/Phase …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Allo-QuadCAR01-T

Snippet

Sponsor: AvenCell Therapeutics, Inc. | Conditions: Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma | Phase 1, Phase 2 | Status: RECRUITING